Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Alpa Laboratories
Small Cap•453 Employees•IPO 2007
Current Price
₹64.40
-1.61 (-2.44%)Updated
Today's Range
₹62.00
₹66.80
₹64.40
52 Week Range
52W Low₹61.00
52W High₹120.50
₹64.40
Downside5.57%
Upside87.11%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹148.02 Cr
Market Cap
Total market value of companyP/E Ratio
7.80
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
1.02
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹8.84
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
-1.16%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
15.80%
ROCE
Return on Capital Employed. >15% is goodNet Margin
16.70%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
60.11%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
7.59%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
-10.90%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
131.00%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
-
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹81.48
Book Value
Net asset value per shareDividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
57.30%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
5 points- •Virtually debt-free status (Debt-to-Equity 0.00) ensures strong financial stability.
- •Quarterly profit after tax surged 131.00%, demonstrating robust recent profitability.
Weaknesses
5 points- •Quarterly sales declined 10.90%, raising concerns about recent revenue generation.
- •Operating Profit Margin (OPM) is low at 4.26%, indicating operational inefficiencies.
Opportunities
4 points- •Expanding Pharmaceuticals and Healthcare sector offers significant market growth potential.
- •Low P/E ratio of 7.22 presents opportunity for valuation re-rating by investors.
Threats
5 points- •Intense competition from larger, established pharmaceutical players like Sun Pharma.
- •Regulatory changes in the pharmaceutical industry could impact profitability and operations.
Segment-wise Financial Analysis
Financial Results
Balance Sheet
Standalone • Annual • All amounts in ₹ Crores • CA Schedule III Format
No Balance Sheet Data Available
Standalone annual data is not available for this symbol.
Try switching to Consolidated view.
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
Recent Insider Transactions
| Insider Name | Transaction Date | Filing Date | Total Shares | Change | Price | Action |
|---|---|---|---|---|---|---|
Paresh Chawla | 17 Jun 2025 | 17 Jun 2025 | 72.08 L | 35.22 L | - | BUY |
Mahendra Singh Chawla | 17 Jun 2025 | 17 Jun 2025 | 1,000 | 29.06 L | - | SELL |
Asha Chawla | 17 Jun 2025 | 17 Jun 2025 | 700 | 6.16 L | - | SELL |
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹76.40 | +₹12.00 | +18.63% |
| R3 | ₹71.60 | +₹7.20 | +11.18% |
| R2 | ₹69.20 | +₹4.80 | +7.45% |
| R1 | ₹66.80 | +₹2.40 | +3.73% |
| PIVOT | ₹64.40 | 0.00 | 0.00% |
| CURRENT | ₹64.40 | - | - |
| S1 | ₹52.40 | -₹12.00 | -18.63% |
| S2 | ₹57.20 | -₹7.20 | -11.18% |
| S3 | ₹59.60 | -₹4.80 | -7.45% |
| S4 | ₹62.00 | -₹2.40 | -3.73% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume+104.3% vs avg
0.43L
(02 Mar 2026)Delivery %+9.8% vs avg
74.7%
(02 Mar 2026)Avg Volume (20D)20-day average
0.21L
(03 Feb - 02 Mar)Avg Delivery %Trend ↑
64.8%
(03 Feb - 02 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Sun Pharmaceutical Industries Ltd
1.16 %
Highest Dividend Yield
Sun Pharmaceutical Industries Ltd
0.91 %
Peer Comparison
| Company Name |
|---|
 Krebs Biochemicals & Industries Ltd |
 Sun Pharmaceutical Industries Ltd |
About
Alpa Laboratories Ltd
ALPA Laboratories Limited is an Indian pharmaceutical company specializing in the manufacturing and sale of finished dosage forms of pharmaceutical products. Their product portfolio is diverse, encompassing a wide range of therapeutic categories and dosage forms to serve both human and veterinary healthcare needs.
The company's product offerings include ethical, generic, and over-the-counter (OTC) medications. These are available in various forms such as injections, tablets, capsules, topical preparations (creams, gels, ointments), and ophthalmic and otic (eye and ear) drops. The therapeutic categories covered are extensive and include anti-infectives (antibacterial, antibiotics, antifungals, antiprotozoals, and antivirals), analgesics, anti-inflammatory drugs, cough and cold medications, cardiovascular drugs, anti-diabetics, nutritional supplements, psychotropic drugs, and skincare preparations including ear and eye care products.
ALPA's distribution network is robust, utilizing a multi-channel approach to reach its customers. This includes collaborations with distributors, retail chemists, retail pharmacy stores, and hospitals within India. Furthermore, the company actively engages in international trade, exporting its products to various regions including South and Central America, Africa, Asia, Russia, Ukraine, and Kazakhstan, demonstrating a significant global reach.
Established in 1967 and headquartered in Indore, India, ALPA Laboratories Limited has a long history in the pharmaceutical industry. Its comprehensive product range, established distribution network, and international presence solidify its position as a significant player in the Indian and global pharmaceutical markets.
COMPANY FACTS - ALPA
Registered Address
33/2 Pigdamber, A.B. Road, Rau
Indore
MADHYA PRADESH
IN
Tel: 917314294567
Website:http://www.alpalabs.in/
Investor Relations:http://www.alpalabs.in/financials.html
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 453
IPO Date: 01/08/2007
MANAGEMENT - ALPA
Mr. Purushottam Patel
Chairman of the Board
Jayesh Patel
Chief Executive Officer
Bakulesh Shah
Chief Financial Officer
Mr. Paresh Chawla
Managing Director, Director
Mahendra Chawla
Whole-Time Director
Pravin Shah
Whole Time Director
Mr. Shitul Shah
Additional Director
Shashi Jain
Woman Director
Devendra Baheti
Non-Executive Independent Director
Mr. Saket Baheti
Additional Non-Executive Independent Director
Mrs. Jyoti Jain
Additional Non-Executive Independent Director
Mrs. Pratibha Lunawat
Additional Non-Executive Independent Director
Investor Questions Answered
Alpa Laboratories Ltd (ALPA) Stock FAQs
Get answers to the most common questions about Alpa Laboratories Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Alpa Laboratories Ltd (ALPA) is ₹64.4. Today, the stock has declined by ₹1.61 (2.44%), trading in a range of ₹62 to ₹66.8. The stock opened at ₹66.8 with a trading volume of 42,752 shares.
Alpa Laboratories Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹148.02 crores, P/E ratio of 7.80, ROE of -1.16%, and ROCE of 15.80%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Alpa Laboratories Ltd (ALPA) is ₹120.5, while the 52-week low is ₹61. Currently trading at ₹64.4, the stock is 5.7% away from its 52-week low and 46.6% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Alpa Laboratories Ltd stock at ₹64.4 depends on multiple factors. The stock is currently trading with a P/E ratio of 7.80 and P/B ratio of N/A. Today's performance shows a loss of 2.44%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Alpa Laboratories Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹64.4, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Alpa Laboratories Ltd's key financial metrics include: P/E Ratio: 7.80, P/B Ratio: N/A, ROE: -1.16%, ROCE: 15.80%, Dividend Yield: 0.00%, EPS: ₹8.84, Book Value: ₹81.48, Debt-to-Equity: 0.00, and Current Ratio: N/A. The company's market cap stands at ₹148.02 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Alpa Laboratories Ltd stock opened at ₹66.8 and is currently trading at ₹64.4, showing a decline of ₹1.61 (2.44%). The intraday high is ₹66.8 and low is ₹62. The trading volume stands at 42,752 shares, indicating moderate market participation today.
Alpa Laboratories Ltd has a Price-to-Earnings (P/E) ratio of 7.80, which means investors are willing to pay ₹7.80 for every ₹1 of earnings. With an EPS of ₹8.84, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
Alpa Laboratories Ltd has a market capitalization of ₹148.02 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹64.4) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Alpa Laboratories Ltd has a book value of ₹81.48 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹64.4, which is 21.0% below the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Alpa Laboratories Ltd has a Return on Equity (ROE) of -1.16% and Return on Capital Employed (ROCE) of 15.80%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Alpa Laboratories Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Alpa Laboratories Ltd has a debt-to-equity ratio of 0.00, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Alpa Laboratories Ltd has an Earnings Per Share (EPS) of ₹8.84, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹64.4 and P/E ratio of 7.80, investors are paying 7.80 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Alpa Laboratories Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Alpa Laboratories Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Alpa Laboratories Ltd stock, consider: 1) Fundamental Analysis - Review P/E (7.80), ROE (-1.16%), debt-to-equity (0.00), and growth rates. 2) Technical Analysis - Check 52-week range (₹61.00 - ₹120.50), moving averages, and chart patterns. 3) Valuation - Compare current price (₹64.40) with book value (₹81.48) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Alpa Laboratories Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹64.4 is 544x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Alpa Laboratories Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹61.00 - ₹120.50). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.00 indicates leverage. 4) Liquidity Risk - Based on trading volume of 42,752 shares. 5) Valuation Risk - P/E of 7.80 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Alpa Laboratories Ltd operates in the industry with key metrics: P/E ratio of 7.80, ROE of -1.16%, market cap of ₹148.02 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.00), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Alpa Laboratories Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹64.4, with a 52-week range of ₹61.00 to ₹120.50. Based on fundamentals like P/E (7.80), ROE (-1.16%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Alpa Laboratories Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹64.40. 2) Fundamental Deterioration - Declining ROE (currently -1.16%), increasing debt (D/E: 0.00), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Alpa Laboratories Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu